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The incidence rate of hepatic decompensation was higher in
patients with human immunodeficiency virus (HIV)/hepati-
tis B virus (HBV)/hepatitis C virus (HCV) triple infection
than in those with HIV/HCV coinfection (24.1 vs 10.8 events
per 1000 person-years; hazard ratio [HR], 1.89; 95% confi-
dence interval [CI], 1.12–3.18). Compared with HIV/HCV-
infected patients, the rate of decompensation was increased
among HIV/HBV/HCV-infected patients receiving no anti-
HBV therapy (HR, 2.48; 95% CI, 1.37–4.49) but not among
those who did receive such therapy (HR, 1.09; 95% CI,
.40–2.97)
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Owing to shared routes of transmission, hepatitis B virus (HBV)
infection may also be present in patients with human immu-
nodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection
[1–5]. However, few studies have compared rates of hepatic
decompensation between patients with HIV/HBV/HCV triple
infection and those with HIV/HCV dual infection. Mechanisti-
cally, HBV infection could either increase or have little effect on
the rate of hepatic decompensation among HIV/HCV-coinfected
persons. Chronic HBV infection might exacerbate immune-
mediated hepatic inflammation and fibrosis and increase the
risk of hepatic decompensation in HIV/HCV-infected patients
[6]. Alternatively, because replication of one hepatitis virus usu-
ally predominates over the other in coinfected persons [7–10],
the reciprocal inhibitory effect of hepatitis viruses might lead to
comparable decompensation rates in HIV/HBV/HCV-infected
and HIV/HCV-infected patients. Moreover, it remains unclear
whether rates of decompensation in HIV/HBV/HCV-infected
patients receiving anti-HBV nucleos(t)ide analogue therapy
are similar to those of HIV/HCV-infected patients.
We first compared rates of hepatic decompensation in HIV/
HBV/HCV-infected and HIV/HCV-infected patients. We then
determined the risk of decompensation associated with anti-
HBV nucleos(t)ide analogue-untreated and treated HIV/
HBV/HCV infection compared with HIV/HCV infection.
METHODS
We conducted a retrospective cohort study among patients with
HIV/HBV/HCV triple infection and those with HIV/HCV co-
infection in the Veterans Health Administration (VA) between
1 October 2005 and 28 February 2012. Data within the VA’s na-
tional Medical SAS Dataset, Pharmacy Benefits Management
files, and Decision Support System were evaluated [11, 12], in-
cluding hospital and outpatient International Classification of
Diseases, Ninth Revision (ICD-9) diagnoses, laboratory results,
and dispensed medications. Death date was determined using
the VAVital Status file. This study was approved by the Univer-
sity of Pennsylvania Institutional Review Board.
HIV/HBV/HCV-infected patients had: (1) HIV (HIV ICD-9
diagnosis, positive HIV antibody/RNA result, or prescriptions
for antiretroviral therapy (ART), defined as use of ≥3 antiretro-
virals from 2 classes [13]); (2) detectable HCV RNA (HCV RNA
>650 IU/mL or positive qualitative HCVRNA result); (3) chronic
HBV (2 chronic HBV ICD-9 diagnoses, 2 positive HBV surface
antigen results, or a positive HBV surface antigen result and
chronic HBV ICD-9 diagnosis that each had to be recorded >6
months apart, or a prescription for a nonantiretroviral anti-HBV
nucleos(t)ide analogue [ie, adefovir, entecavir, or telbivudine]),
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and (4) ≥12 months in the VA system. HIV/HCV-infected pa-
tients had: (1) HIV infection; (2) detectable HCV RNA; (3) ≥12
months in the VA system; and (4) no chronic HBV ICD-9 diag-
nosis, positive HBV surface antigen, or prescriptions for nonan-
tiretroviral anti-HBV nucleos(t)ide analogues. Previously
validated ICD-9 diagnoses used to identify HIV [14] and chron-
ic HBV [15] are listed in Supplementary Appendix 1. Patients
were excluded if they had hepatic decompensation or had re-
ceived interferon-based HCV therapy (because treatment re-
duces the risk of end-stage liver disease [16, 17]) before the
start of follow-up.
Follow-up for both cohorts began after 12 months in the VA
system. The 12 months before the start of follow-up represented
the baseline period. Follow-up continued until first hepatic de-
compensation (defined below), death, HCV treatment initia-
tion, or last visit before 28 February 2012.
The primary outcome was incident hepatic decompensation,
defined by 1 hospital discharge ICD-9 diagnosis or ≥2 outpa-
tient ICD-9 diagnoses of ascites, spontaneous bacterial perito-
nitis, or esophageal variceal hemorrhage (Supplementary
Appendix 2). A prior study validated this definition, with
91% of events confirmed by medical records [18]. Two outpa-
tient diagnoses were required to exclude events that might be
suspected, but not confirmed, at follow-up visits. Based on
the results of the prior validation study [18], we did not include
ICD-9 diagnoses for hepatic encephalopathy or jaundice, which
could indicate decompensation, because these diagnoses were
often linked to unrelated conditions (eg, narcotic overuse, stroke
recorded as encephalopathy, biliary obstruction, or atazanavir-
associated hyperbilirubinemia recorded as jaundice). The de-
compensation date was defined as the hospital discharge date
(if identified by hospital diagnosis) or initial outpatient diagno-
sis date (if identified by outpatient diagnoses).
Baseline data included age, sex, race, ethnicity, body mass
index, diabetes mellitus, alcohol dependence/abuse, injection/
noninjection drug use, HCV RNA level, hepatitis delta virus
ICD-9 diagnosis, CD4 cell count, plasma HIV RNA, use of an-
tiretroviral medications, and use of anti-HBV nucleos(t)ide an-
alogues (ie, adefovir, emtricitabine, entecavir, lamivudine,
telbivudine, or tenofovir). Diabetes [19], alcohol dependence/
abuse [20], and injection/noninjection drug use [20, 21] were
defined by validated ICD-9 diagnoses.
We estimated incidence rates (events per 1000 person-years)
of hepatic decompensation with 95% confidence intervals (CIs)
in each cohort. We used Cox regression to estimate adjusted
hazard ratios (HRs) of decompensation in triply versus dually
infected patients [22]. Potential confounders evaluated included
age, race, ethnicity, body mass index, diabetes, alcohol depen-
dence/abuse, drug use, and HCV RNA level. We then used
Cox regression to determine the risk of decompensation in
anti-HBV nucleos(t)ide analogue-untreated and treated HIV/
HBV/HCV-infectedpatients comparedwithHIV/HCV-infected
patients. Proportionality of hazards was evaluated using plots of
Schoenfeld residuals [23]. Data were analyzed using SAS soft-
ware (version 9.2; SAS Institute).
RESULTS
Between 2005 and 2012, a total of 5051 patients (149 with HIV/
HBV/HCV and 4902 with HIV/HCV infection) met inclusion
criteria (Supplementary Figure 1). Triply infected patients were
more commonly white andHispanic andmore frequently had di-
abetes, alcohol and drug dependence/abuse, and an HCV RNA
level <800 000 IU/mL (Table 1). Similar proportions of both co-
horts had HIV RNA <75 copies/mL and CD4 counts <200 cells/
mm3, but HIV/HBV/HCV-infected patients were more frequent-
ly prescribed ART during the baseline period. Among the 149
triply infected patients, 63 (42.3%) received an anti-HBV
nucleos(t)ide analogue as part of their baseline ART regimen,
most commonly tenofovir in combination with either emtricita-
bine or lamivudine. Seventeen HIV/HBV/HCV-infected patients
(11.4%) also had a diagnosis of hepatitis delta virus infection.
The median follow-up time was longer for triply infected
than for dually infected patients (4.6 vs 4.4 years; P = .03). Dur-
ing follow-up, 15 (10.1%) of the HIV/HBV/HCV-infected and
544 (11.1%) of the HIV/HCV-infected patients started HCV
therapy and were censored. A higher proportion of triply infect-
ed patients died during follow-up (13 [8.7%] vs 209 [4.3%];
P = .009).
Hepatic decompensation occurred more frequently in triply
than in dually infected patients (16 [10.7%] vs 230 [4.7%];
P = .02). At the time of initial decompensation, spontaneous
bacterial peritonitis was less common among triply infected pa-
tients (0/16 [0.0%] vs 18/230 [7.8%]; P < .001). Similar propor-
tions of triply and dually infected patients with hepatic
decompensation presented with ascites (13/16 [81.3%] vs 176/
230 [76.5%]; P = .63) and variceal hemorrhage (6/16 [37.5%] vs
68/230 [29.6%]; P = .53). The unadjusted incidence rate of he-
patic decompensation was higher in triply than in dually infect-
ed patients (24.1 vs 10.8 events per 1000 person-years). After
adjustment for baseline age, ethnicity, diabetes, history of alco-
hol abuse, and HCV RNA level, HIV/HBV/HCV-infected
patients had a higher rate of decompensation than HIV/
HCV-infected patients (HR, 1.89; 95% CI, 1.12–3.18).
Compared to findings in HIV/HCV-infected patients, the rate
of decompensation was increased for triply infected patients with
no anti-HBV nucleos(t)ide analogue use (HR, 2.48; 95% CI,
1.37–4.49) but not for those receiving an anti-HBV nucleos(t)
ide analogue (HR, 1.09; 95% CI, .40–2.97), after controlling for
age, ethnicity, diabetes, history of alcohol abuse, and HCV
RNA level. No differences in the frequency of decompensation
were observed by anti-HBV regimen prescribed.
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DISCUSSION
In this study, HIV/HBV/HCV-infected patients had higher
rates of hepatic decompensation than HIV/HCV-infected pa-
tients. Specifically, the risk of decompensation was increased
among triply infected patients who did not receive an anti-
HBV-active nucleos(t)ide analogue.
Our findings are consistent with those of prior studies eval-
uating liver-related outcomes among HIV/HBV/HCV-infected
patients. A cohort study from the United States found that liver-
related deaths occurredmore frequently among patients with HIV/
HBV/HCV infection than among those with either HIV/HCV or
HIV infection alone [1]. Similarly, a cross-sectional study from
Spain showed that HIV/HBV/HCV-infected patients had a higher
prevalence of cirrhosis than HIV/HBV- or HIV/HCV-infected pa-
tients [2]. Another cohort study from Spain observed that HIV/
HBV/HCV-infected patients had higher rates of cirrhosis and he-
patic decompensation than HIV/HBV-infected patients [24].





(n = 4902) P Value
Age, median (IQR), y 52 (48–56) 53 (49–57) .19
Male sex, No. (%) 146 (98.0) 4790 (97.7) .83
Race, No. (%)
Black 62 (41.6) 2106 (43.0) .74
White 51 (34.2) 878 (17.9) <.001
Other/unknown 36 (24.2) 1918 (39.1) <.001
Hispanic ethnicity 32 (21.5) 286 (5.8) <.001
BMI, median (IQR), kg/m2 25.3 (22.6–28.5) 25.7 (23.2–28.9) .22
Diabetes mellitus, No. (%) 31 (20.8) 681 (13.9) .02
History of alcohol dependence/abuse, No. (%) 46 (30.9) 1027 (21.0) .004
History of injection/noninjection drug use, No. (%) 88 (59.1) 1961 (40.0) <.001
HCV RNA level, No. (%)a
≥800 000 IU/mL 96 (64.4) 3529 (72.0) .04
<800 000 IU/mL 43 (28.9) 1061 (21.6) .04
Qualitative result only 10 (6.7) 312 (6.4) .86
HIV RNA level
Median (IQR), log copies/mL 4.1 (2.8–5) 4.3 (2.7–5) .75
<75 copies/mL, No. (%) 60 (40.3) 1657 (33.8) .10
CD4 cell count
Median (IQR), cells/mm3 356 (206–561) 378 (204–568) .81
<200 cells/mm3, No. (%) 15 (10.1) 492 (10.0) .99
Prescribed ART, No. (%)
During baseline period 84 (56.4) 2332 (47.6) .03
Ever 114 (76.5) 3470 (70.8) .13
Anti-HBV nucleos(t)ide analogue use, No. (%)b
During baseline period 63 (42.3) 1510 (30.8) .003
Ever 103 (69.1) 2809 (57.3) .004
Baseline anti-HBV nucleos(t)ide analogue regimens,
No. (%)c
Tenofovir and emtricitabine 30 (20.1) 789 (16.1) .20
Tenofovir and lamivudine 24 (16.1) 464 (9.5) .007
Tenofovir alone 0 (0.0) 5 (0.1) .047
Lamivudine alone 1 (0.7) 65 (1.3) .49
Other 18 (12.1) 449 (9.2) .23
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus;
IQR, interquartile range.
a Based on highest baseline HCV RNA result.
b Defined by dispensed prescription for adefovir, emtricitabine, entecavir, lamivudine, telbivudine, or tenofovir.
c Patients may have been receiving >1 regimen during the baseline period.
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Our observation that HIV/HBV/HCV-infected patients
receiving anti-HBV nucleos(t)ide analogue therapy did not
have a higher rate of decompensation than HIV/HCV-infected
patients demonstrates the effect of anti-HBV treatment on liver-
related complications. This finding supports the recommenda-
tion that all HIV/HBV-coinfected patients should start and
continue anti-HBV-active ART, regardless of CD4 count [13].
These guidelines state that the optimal ART regimen for HBV-
coinfected persons should include tenofovir and emtricitabine
(or lamivudine) as the preferred nucleos(t)ide backbone. If te-
nofovir cannot safely be used, entecavir is an alternative if used
with a fully suppressive ART regimen.
This study has several potential limitations. Decompensation
outcomes could have been misclassified, but the risk of misclas-
sification was minimized by using a previously validated defini-
tion [18, 25]. Because this definition did not include hepatic
encephalopathy diagnoses, the number of decompensation
events might have been underestimated. However, the negative
predictive value of the definition exceeded 99% [18]. Second,
residual confounding by unmeasured factors (eg, duration of
HIV infection and viral hepatitis, tobacco use, and alcohol de-
pendence/drug use during follow-up) is possible. Moreover,
hepatitis B e antigen, hepatitis B e antibody, and hepatitis B
DNA were only rarely measured in clinical practice, so we
could not evaluate the influence of these variables on decom-
pensation events, particularly the effectiveness of anti-HBV-
active ART. Finally, our sample included predominantly male
US veterans, and results may not be generalizable to women.
In conclusion, HIV/HBV/HCV-infected patients had higher
rates of hepatic decompensation than HIV/HCV-infected pa-
tients. The risk of decompensation was increased among triply
infected patients who did not receive anti-HBV nucleos(t)ide
analogue therapy. Providers should ensure that HIV/HBV/
HCV-infected patients receive anti-HBV-active ART to reduce
rates of decompensated cirrhosis in this population.
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